argenx SE (ARGX) climbs after positive Phase 3 ALKIVIA data for efgartigimod in autoimmune myositis. The biotech also backed the move with strong Q2 sales growth, an earnings beat, and a pipeline that continues to expand beyond its lead autoimmune franchise.
argenx SE (ARGX) climbs 11.6% in extended-hours trading after reporting positive Phase 3 ALKIVIA results for efgartigimod in autoimmune myositis. The clinical win strengthens the company’s immunology pipeline and adds to a backdrop of strong sales growth and an earnings beat, though the stock’s premium valuation means investors should watch for regular-session confirmation before chasing the move.
argenx SE (NASDAQ: ARGX) climbs 11.60% in extended-hours trading to $950, up from the prior regular-session close of $851.29. The jump follows positive Phase 3 ALKIVIA trial results for efgartigimod in autoimmune myositis, giving the commercial-stage biotech a fresh pipeline win; regular-session trading will confirm whether the after-hours gain holds.
Key Takeaways
ARGX reached $950 in extended-hours trading, placing the stock close to its 52-week high of $953.58.
The main catalyst is ALKIVIA, a Phase 3 autoimmune myositis trial that met its primary endpoint with p=0.0011.
Q2 product net sales reached $1.5B, up 60% year over year, while EPS beat estimates by 19.4%.
The $52.94B market cap and 32.45 P/E reflect a premium growth valuation, so price discipline matters after the surge.
The trial win strengthens argenx's immunology platform, while the Forte Biosciences deal adds another pipeline asset.
What's Behind ARGX's After-Hours Rally: Positive ALKIVIA Myositis Data
The clearest reason for ARGX's move is argenx's August 17 announcement of positive topline results from the Phase 3 ALKIVIA trial. The study tested efgartigimod in patients with autoimmune myositis, including immune-mediated necrotizing myopathy and dermatomyositis.
ALKIVIA met its primary endpoint at Week 52 in the combined study population. The result reached statistical significance with p=0.0011. Argenx also reported early and sustained patient improvements across both disease groups.
The result carries extra weight because the company described it as the first Phase 3 study to show statistically significant and clinically meaningful improvements in disease activity for immune-mediated necrotizing myopathy, a subtype without an approved therapy.
This is a direct company-specific catalyst, unlike a routine momentum move or a broad biotech-sector rotation. The data expands the possible commercial reach of efgartigimod and adds another clinical proof point for argenx's antibody-driven immunology strategy.
argenx SE Financials Show a Commercial-Stage Growth Engine
ARGX enters this trial announcement with strong operating momentum. In its July 23, 2026 second-quarter update, argenx reported $1.5B in global product net sales. Sales rose 60% year over year and 17% from the previous quarter.
The earnings record adds support to the growth story. Second-quarter EPS came in at $7.32 versus a $6.13 estimate, producing a 19.4% positive surprise. The company has beaten EPS estimates in six of the last seven reported quarters.
argenx is not a pre-revenue biotech waiting for one trial to validate its model. Its commercial products include VYVGART and VYVGART HYTRULO, which target autoimmune diseases such as generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy.
The FDA expanded VYVGART and VYVGART HYTRULO to all adult patients with generalized myasthenia gravis on May 8, 2026. That label expansion, combined with $1.5B in quarterly product sales, gives the business a revenue base while the pipeline develops.
ARGX Valuation and Competitive Position After the Myositis Breakthrough
At the $950 extended-hours print, ARGX carries a $52.94B market cap and a 32.45 P/E. That valuation reflects more than current VYVGART sales. It also prices in continued execution, label expansion, and meaningful value from future immunology programs.
The price sits just below the 52-week high of $953.58. That positioning shows strong momentum, but it also leaves less room for a weak clinical update or slower commercial growth. A great company and a great entry price remain separate ideas, a distinction markets often rediscover with theatrical timing.
Analyst targets provide a useful reference point. Recent targets range from $932 to $1,350, with a consensus target of $1,089.91. Wells Fargo raised its target to $1,350, while Morgan Stanley lifted its target to $1,200 and Wedbush raised its target to $1,050 after the July results.
The competitive advantage rests on a commercial product franchise plus a broad autoimmune pipeline. The July 27 agreement to acquire Forte Biosciences for about $2.2B adds FB102, described as a first-in-class anti-CD122 antibody. That transaction gives argenx another mechanism and reduces reliance on a single development path.
How Investors Can Approach ARGX After the $950 Move
The first practical step is to separate the quality of the catalyst from the speed of the price reaction. ALKIVIA delivered a statistically significant Phase 3 result, but the stock also jumped from $851.29 to $950 in extended-hours trading. That gap creates a sharper near-term valuation test.
A disciplined approach favors confirmation over chasing. Regular-session volume, price retention, and the stock's ability to remain near the $953.58 52-week high will show whether buyers accept the new level. Extended-hours trading often has thinner liquidity, so the regular session provides the cleaner read.
The second step is to track commercial execution against the 32.45 P/E. The $1.5B Q2 product-sales figure and 60% annual growth rate support the premium. However, the valuation still requires strong delivery from VYVGART, VYVGART HYTRULO, and the broader pipeline.
The third step is to follow the next named pipeline milestone. Argenx identified the EMPASSION multiple sclerosis and multifocal motor neuropathy program's topline readout for the fourth quarter of 2026. That event adds a defined test for the platform after the ALKIVIA success.
For existing holders, the trial result strengthens the long-term business case, while the near-52-week-high price argues for measured position sizing. For new buyers, staged exposure offers a cleaner way to manage a stock that has already priced in substantial optimism.
ARGX climbs because ALKIVIA delivered a concrete Phase 3 win, not because of vague biotech enthusiasm. Strong Q2 sales, a recent EPS beat, an expanding immunology portfolio, and a $1,089.91 analyst consensus target support the narrative, but the 32.45 P/E demands continued execution. The after-hours move is powerful; regular-session confirmation and disciplined entry prices will determine how investable it becomes.
ARGX is rising after argenx reported positive Phase 3 ALKIVIA trial results for efgartigimod in autoimmune myositis. The data met the primary endpoint and improved the company’s pipeline outlook.
+Should I buy ARGX stock now?
The stock has a strong catalyst, but it is already near its 52-week high and trades at a premium valuation. A staged entry or waiting for regular-session confirmation is the more disciplined approach.
+What did the ALKIVIA trial show for argenx?
ALKIVIA met its primary endpoint at Week 52 with statistical significance. Argenx said the study showed early and sustained improvements in patients with autoimmune myositis.
+Is argenx still growing as a business?
Yes. The company reported $1.5 billion in Q2 product net sales, up 60% year over year, and beat EPS estimates. That gives ARGX a commercial base while its pipeline advances.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
▌The Full Report
Want the full picture on ARGX?
The analyst-grade research report — charts, grades, valuation, and price targets — in 10 minutes.
